



Dieter Koeberle

Kontakt

Dieter Koeberle

Publikationen (13)

Adamina M, Warlaumont M, Berger M, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt C, Hübner M. Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. *Cancers (Basel)* 2022; 14

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. *J Geriatr Oncol* 2018; 10:304-310.

von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). *Eur J Cancer* 2017; 89:82-89.

Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. *Clin Colorectal Cancer* 2017

Zumstein V, Vinzens F, Zetti A, Heinimann K, Koeberle D, von Flüe M, Bolli M. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients. *Swiss Med Wkly* 2016; 146:w14315.

Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhovir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015; 10:1451-7.

Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. *J Pain Symptom Manage* 2014; 48:1160-7.

Worni M, Gueller U, White R, Castleberry A, Pietrobon R, Cerny T, Gloor B, Koeberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. *Pancreas* 2013; 42:1157-63.

Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. *Support Care Cancer* 2013; 21:3085-93.

Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3702-8.

Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3695-701.

Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B. Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23:8547-8.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch